New trial hopes to stop lung transplant failure before it starts
NCT ID NCT07410312
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests whether adding the anti-inflammatory drug Anakinra to the solution that donor lungs are stored in can prevent primary graft dysfunction — a serious complication after lung transplant that causes low oxygen and lung inflammation. The study will enroll 20 lung transplant recipients and measure outcomes like graft function on day 3, ICU stay, and hospital stay. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anakinra (a drug that blocks inflammation)
- What this could lead to
- If it works, this could reduce the risk of severe lung injury right after transplant, potentially improving recovery and shortening hospital stays.
- What could go wrong
- This is a very early, small trial (20 people) testing a new use for an existing drug. It may not show clear benefit, and results may not apply to all transplant patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT RECIPIENT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.